Latest Information Update: 18 Mar 2016
At a glance
- Originator NGM Biopharmaceuticals
- Class Antihyperglycaemics; Monoclonal antibodies; Obesity therapies
- Mechanism of Action Immunomodulators; Type 1 fibroblast growth factor receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Obesity
Most Recent Events
- 01 Feb 2016 Phase-I clinical trials in Obesity (In volunteers) in Australia (Parenteral) (NCT02708576)